Molecular Partners AG

LSE:0QXX Stock Report

Market Cap: CHF 163.3m

Molecular Partners Management

Management criteria checks 2/4

Molecular Partners' CEO is Patrick Amstutz, appointed in Jan 2004, has a tenure of 7.25 years. total yearly compensation is CHF1.05M, comprised of 36.8% salary and 63.2% bonuses, including company stock and options. directly owns 1.99% of the company’s shares, worth CHF3.26M. The average tenure of the management team and the board of directors is 3.5 years and 4.8 years respectively.

Key information

Patrick Amstutz

Chief executive officer

CHF 1.0m

Total compensation

CEO salary percentage36.8%
CEO tenure21yrs
CEO ownership2.0%
Management average tenure3.5yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Patrick Amstutz's remuneration changed compared to Molecular Partners's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CHF 63m

Jun 30 2024n/an/a

-CHF 58m

Mar 31 2024n/an/a

-CHF 59m

Dec 31 2023CHF 1mCHF 385k

-CHF 62m

Sep 30 2023n/an/a

-CHF 60m

Jun 30 2023n/an/a

-CHF 62m

Mar 31 2023n/an/a

-CHF 50m

Dec 31 2022CHF 1mCHF 383k

CHF 118m

Sep 30 2022n/an/a

CHF 117m

Jun 30 2022n/an/a

CHF 118m

Mar 31 2022n/an/a

CHF 106m

Dec 31 2021CHF 1mCHF 380k

-CHF 64m

Sep 30 2021n/an/a

-CHF 67m

Jun 30 2021n/an/a

-CHF 72m

Mar 31 2021n/an/a

-CHF 66m

Dec 31 2020CHF 1mCHF 380k

-CHF 63m

Sep 30 2020n/an/a

-CHF 53m

Jun 30 2020n/an/a

-CHF 48m

Mar 31 2020n/an/a

-CHF 43m

Dec 31 2019CHF 930kCHF 363k

-CHF 36m

Sep 30 2019n/an/a

-CHF 37m

Jun 30 2019n/an/a

-CHF 38m

Mar 31 2019n/an/a

-CHF 38m

Dec 31 2018CHF 909kCHF 346k

-CHF 37m

Compensation vs Market: Patrick's total compensation ($USD1.15M) is above average for companies of similar size in the UK market ($USD718.82K).

Compensation vs Earnings: Patrick's compensation has increased whilst the company is unprofitable.

CEO

Patrick Amstutz (49 yo)

21yrs

Tenure

CHF 1,047,000

Compensation

Dr. Patrick Amstutz, Ph.D. is a Co-Founder of Molecular Partners AG and has been its Chief Executive Officer since November 2016 and serves as its Member of Management Board since 2004. Dr. Amstutz serves...

Leadership Team

NamePositionTenureCompensationOwnership
Patrick Amstutz
Co-Founder21yrsCHF 1.05m1.99%
CHF 3.3m
Michael Stumpp
Co-Founder21yrsno data2.08%
CHF 3.4m
Robert Hendriks
Senior VP of Finance5.5yrsno datano data
Alexander Zurcher
COO & Member of Management Board2.5yrsno data0.070%
CHF 113.9k
Renate Gloggner
Executive VP of People & Community and Member of Management Board3.1yrsno data0.062%
CHF 101.9k
Daniel Steiner
Senior Vice President of Research & Technology3.8yrsno datano data
Seth Lewis
Senior Vice President of Investor Relationsno datano datano data
Michael Pitzner
General Counsel2.2yrsno datano data
Pamela Trail
Strategic Consultant5.5yrsno datano data
Anne Goubier
Senior Vice President of Research & Early Development3yrsno datano data
Philippe Legenne
Chief Medical Officer1.4yrsno datano data

3.5yrs

Average Tenure

52yo

Average Age

Experienced Management: 0QXX's management team is considered experienced (3.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Patrick Amstutz
Co-Founder7.3yrsCHF 1.05m1.99%
CHF 3.3m
Steven H. Holtzman
Independent Non Executive Director10.7yrsCHF 135.00k0.040%
CHF 65.2k
William A. Burns
Independent Chairman of the Board7.3yrsCHF 295.00k0.073%
CHF 119.4k
Vito Palombella
Independent Director4.8yrsCHF 125.00k0.0095%
CHF 15.5k
Agnete Fredriksen
Independent Director3.8yrsCHF 125.00kno data
Michael Vasconcelles
Independent Director4.8yrsCHF 135.00k0.0095%
CHF 15.5k
Sandip Kapadia
Independent Director4.8yrsCHF 130.00k0.0095%
CHF 15.5k
Dominik Hochli
Independent Director3.8yrsCHF 133.00kno data

4.8yrs

Average Tenure

59yo

Average Age

Experienced Board: 0QXX's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 03:23
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Molecular Partners AG is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Maurizio BernasconiBank am Bellevue
null nullCredit Suisse
Thomas KaufmannCredit Suisse